Literature DB >> 22609442

Polymorphisms of genes related to endothelial cells are associated with primary biliary cirrhosis patients of Cretan origin.

Ai Mantaka1, G N Goulielmos, M Koulentaki, O Tsagournis, A Voumvouraki, E A Kouroumalis.   

Abstract

BACKGROUND: Primary biliary cirrhosis (PBC) is an organ specific autoimmune disease of still unidentified genetic etiology. We have shown that endothelins (ETs), produced by the liver endothelial cells are increased in PBC and may play a major pathogenetic role. AIMS: To study gene polymorphisms related to the endothelial cells (eNOS, EDN-1 genes) and, to investigate whether the previously reported association of CTLA4 gene polymorphisms is replicated in a genetically homogeneous Greek population. PATIENTS AND METHODS: Genomic DNA was extracted from 100 PBC patients (83 females, 93% AMA+, 74/100 Ludwig stage I-II) and 158 healthy controls. eNOS, CTLA4 and ET1 polymorphisms were determined by PCR-RFLPs analysis.
RESULTS: Both eNOS intron4 VNTR and eNOS exon7 G894T SNP were significantly associated with increased risk in PBC. EDN-11 rs2071942 "A" and rs5370 "T" alleles appeared a tendency for association with disease progression. No association was found between PBC and the CTLA4 SNPs analyzed.
CONCLUSIONS: We demonstrated that eNOS, a gene related to the liver endothelium function is associated with PBC. Contrarily, the important in adaptive immunity gene CTLA4 was not associated with the disease in the homogeneous population analyzed. These results are compatible partially with our previous hypothesis that defects of the liver endothelial system, leading to endothelin overproduction, may be a fundamental early pathogenetic mechanism in PBC.
Copyright © 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609442     DOI: 10.1016/j.humimm.2012.05.003

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  The association between bile salt export pump single-nucleotide polymorphisms and primary biliary cirrhosis susceptibility and ursodeoxycholic acid response.

Authors:  Rui-rui Chen; Yuan-jun Li; Xin-min Zhou; Lu Wang; Juan Xing; Shuang Han; Li-na Cui; Lin-hua Zheng; Kai-chun Wu; Yong-quan Shi; Zhe-yi Han; Ying Han; Dai-ming Fan
Journal:  Dis Markers       Date:  2014-10-19       Impact factor: 3.434

Review 3.  Genetic Polymorphisms of Cytotoxic T-Lymphocyte Antigen 4 in Primary Biliary Cholangitis: A Meta-Analysis.

Authors:  Xing-Chen Yang; Masayuki Fujino; Song-Jie Cai; Shao-Wei Li; Chi Liu; Xiao-Kang Li
Journal:  J Immunol Res       Date:  2017-05-31       Impact factor: 4.818

4.  Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population.

Authors:  Maria I Zervou; Efsevia Myrthianou; Irene Flouri; Darren Plant; Gregory Chlouverakis; Francesc Castro-Giner; Panayiota Rapsomaniki; Anne Barton; Dimitrios T Boumpas; Prodromos Sidiropoulos; George N Goulielmos
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

5.  The Evaluation of Endothelin-1 and Endothelin Receptor Type A Gene Polymorphisms in Patients with Vitiligo.

Authors:  İlknur Bingül; İkbal Esen Aydıngöz; Pervin Vural; Semra Doğru-Abbasoğlu; Müjdat Uysal
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494

6.  Τhe genetics of juvenile idiopathic arthritis: Searching for new susceptibility loci.

Authors:  Maria I Zervou; Despoina G Dimopoulou; Elias Eliopoulos; Maria Trachana; Polyxeni Pratsidou-Gkertsi; Athena Andreou; Prodromos Sidiropoulos; Demetrios A Spandidos; Alexandros Garyfallos; George N Goulielmos
Journal:  Mol Med Rep       Date:  2017-10-05       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.